Search Results
Honoring a Devoted UFCW “Cancer Kicker”
Frank Meehan spent two decades spearheading the United Food & Commercial Workers’ (UFCW) effort to raise money to defeat blood cancers. As president of the Long Island, NY Local, he was one of the first leaders to act upon the union’s national relationship with The Leukemia & Lymphoma Society (LLS).
Then last spring, in a twist of fate, he ended up losing his life to one of the aggressive leukemias he’d been hoping to see cured.
10 Self-Care Tips to Cope with Isolation and Stress
Whether you are self-quarantining or practicing social distancing, we all are adjusting to a new normal amid the coronavirus disease (COVID-19) pandemic. Everyone reacts differently to stressful situations. As a patient or survivor, you might be experiencing feelings of isolation, uncertainty and anxiety. As a caregiver, you might be feeling overwhelmed with navigating your loved one’s care while looking after your own needs. And as a family member, you might be feeling unsure of how you can help. This is understandable, and you are not alone.
PD1 blockade alone and in combination with BTK/ITK inhibition in patients with refractory and recurrent primary central nervous system lymphoma
We study a rare and aggressive brain cancer called primary central nervous system lymphoma (PCNSL). We are using an emerging knowledge of the genetic basis of PCNSL to develop novel clinical trials exploring the use of targeted and immunotherapy agents in PCNSL patients. These trials include assessment of the activity of a PD-1 inhibitor by itself and in combination with a BTK inhibitor in PCNSL patients, as well as identifying any mechanisms of treatment resistance that may develop.BURLINGTON STORES RAISE RECORD-BREAKING $3.8 MILLION TO HELP FIGHT BLOOD CANCER
Burlington Stores and The Leukemia & Lymphoma Society’s (LLS) 15th consecutive year of partnership in the fight against blood cancers was a huge success, to say the least. As LLS’s #1 National Corporate Partner and Honored Friend, Burlington Stores, surpassed their $3.6 million goal by a longshot raising more than a record-breaking $3.8 million!
Five Reasons to Give Thanks
The Leukemia & Lymphoma Society (LLS) exists to find cures for blood cancers and improve the quality of life of patients and their families. The fervor with which experts, patients and supporters rally around this cause is impressive and it’s only because of that synergy that we’re able to make such significant progress in saving lives.
In the spirit of Thanksgiving, we wanted to share five reasons we are giving thanks this holiday season.
Bortezomib
Bortezomib is FDA approved to treat people with myeloma and for the retreatment of adult patients with myeloma who had previously responded to bortezomib therapy and relapsed at least six months following completion of prior bortezomib treatment. Bortezomib is also approved to treat people with previously untreated mantle cell lymphoma as well as patients who have received at least one prior therapy.
Progress on AML but More Work to Do
A Q&A with Amy Burd, PhD, LLS Vice President of Research Strategy
Today is AML World Awareness Day, a day to acknowledge the struggle to tackle one of the most challenging blood cancers, while shining a light on advances in the prevention, management and treatment of acute myeloid leukemia (AML).
Born with leukemia, Eevie beats the odds and turns four!
After Eevie was born, she was diagnosed with a rare form of childhood blood cancer that affects 1 in 5 million newborns. She was given a 17 percent chance of surviving to age 2. This month, Eevie celebrated her fourth birthday. Each year her mother, Brynne, has shared her progress on this blog (you can read those stories here).
The last year has been incredible. The first word that comes to mind is “freedom.”
A phase 1/2 study of DR-01, an anti-CD94 monoclonal antibody, in patients with large granular lymphocytic leukemia or cytotoxic lymphomas
In November 2022, LLS made an equity investment in Dren Bio to "Support Clinical Development of the DR-01 Program for Rare Leukemia & Lymphoma Indications Including Large Granular Lymphocyte Leukemia (LGLL) and Cytotoxic Lymphomas."
Helping Blood Cancer Patients and Families When It's Needed Most
In honor of Blood Cancer Awareness Month, Dr. Gwen Nichols reflects on our vital work to support blood cancer patients and their families.
Cytarabine
Cytarabine is FDA approved to prevent and treat leukemia that has spread to the meninges (the three membranes that cover the brain and spinal cord). It is also FDA approved for use with other drugs to treat acute myeloid leukemia, acute lymphoblastic leukemia and chronic myeloid leukemia. This medicine may cause a temporary loss of hair in some people. After treatment with cytarabine has ended, normal hair growth should return.
Liposomal cytarabine (DepoCyt®) is given by intrathecal injection. It is FDA approved to treat lymphoma that has spread to the meninges.
Predictors of response to therapy in A051902, a US Intergroup study of duvelisib+CHO(E)P vs CC-486+CHO(E)P vs CHO(E)P in peripheral T-cell lymphoma
We are evaluating if adding duvelisib or azacitidine to standard chemotherapy increases the complete remission rate compared to chemotherapy alone in peripheral T-cell lymphoma. We believe that adding novel agents to chemotherapy will most benefit lymphomas with a T-follicular helper phenotype. We will also study if tests for lymphoma cells in the blood can predict outcomes. We hope these novel therapies will cure more patients and we can identify who is most likely to benefit from them.Announcing a New Light The Night T-shirt Contest Winner, Drumroll Please…
The Leukemia & Lymphoma Society (LLS) has officially tallied up the votes for the 2016 Light The Night t-shirt contest submissions, and the winning design comes from 37-year-old Joshua Redmond of Centerville, Ohio.
A graduate of Ohio University’s School of Fine Art, Redmond earned his degree in graphic design and printmaking and has been working professionally in the industry for over a decade.
Surviving Chemo: A Little Planning Goes a Long Way
Just the thought of chemotherapy can be enough to make one feel sick. Toxic drugs powerful enough to kill or damage cancer cells also take their toll on healthy cells. While everyone tends to respond differently, most agree the treatments come with unpleasant side effects.
Check out these 14 tips from The Leukemia & Lymphoma Society that should help make the experience a little less uncomfortable:
FDA Approves New Maintenance Treatment for AML
Some promising news to kick off Blood Cancer Awareness Month – on September 1, 2020, the U.S. Food and Drug Administration approved a new oral maintenance treatment for certain adult patients with acute myeloid leukemia (AML).
CC-486 (Onureg®) is now approved for the continued treatment of adult patients with AML who achieved first complete remission (CR) or CR with incomplete blood count recovery (Cri) following intensive induction chemotherapy and who are not able to undergo intensive curative therapy, such as hematopoietic stem cell transplant.
Beat AML in the Time of COVID-19: A Powerful New Video
Like many clinical trials across the U.S. and the globe, The Leukemia & Lymphoma’s Beat AML Master Trial has been dramatically impacted by the COVID-19 pandemic and has had to make adjustments to continue to provide critical treatment to patients who were previously enrolled.
A Groundbreaking Trial
NBA Sideline Reporter Craig Sager’s Message of Hope at LLS Blood Cancer Conference
A week after receiving the Jimmy V Perseverance ESPY Award, presented by Vice President Biden, where he delivered an emotional speech about his cancer battle, NBA Sideline Reporter Craig Sager again exhibited his #SagerStrong attitude as keynote speaker at The Leukemia & Lymphoma Society’s (LLS) Atlanta Blood Cancer Conference. Sager was diagnosed with acute myeloid leukemia (AML) in 2014. He announced this past march that his cancer is no longer in remission.
